# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
To gain an edge, this is what you need to know today.
TD Cowen analyst Brendan Smith maintains Novavax (NASDAQ:NVAX) with a Hold and raises the price target from $5 to $10.
HC Wainwright & Co. analyst Vernon Bernardino reiterates Novavax (NASDAQ:NVAX) with a Buy and maintains $19 price target.